Home | Publications | Country | Asia / Pacific | India place holder
place holder place holder

India

Indian Pharmaceutical and Healthcare Market Annual Review

2005

Publication Date   May 2005
Publisher   RNCOS
Product Type   Report
Pages   75
ISBN Number   not applicable
Product Code   RCS008
Ask a question about this product?

Price £745.00

approximately: $1,315 | €945

Summary


The recent regulatory and much awaited patent law changes have lead the Indian Pharmaceutical Industry towards exploring newer avenues of drug development, thus, promising higher capital investment in the pharmaceutical industry in the near future. The Indian Pharmaceutical Research is backed by strong Government support and availability of surplus skilled technical workers at lower costs.

At a growth rate of 9 per cent per year, the pharmaceutical industry in India is well set for rapid expansion. As a result of the expansion, the Indian pharmaceutical and healthcare market is undergoing a spurt of growth in its coverage, services, and spending in the public and private sectors. The healthcare market has opened a window of opportunities in the medical device field and has boosted clinical trials in India.

Many multinational companies have penetrated into India with an aim to market drugs and conduct clinical trails. Thus, Indian pharmaceutical research, manufacturing, and outsourcing have received an impetus, thereby, creating an image of a potential healthcare market and a land of opportunities in pharmaceuticals. The economic liberalization policies coming to force in the 1990s and the strong emergence of private sector in the Indian economy has heightened the pace of development of the pharmaceutical industry and will continue to do so.

RNCOS's market research report titled, "Indian Pharmaceutical and Healthcare Market-Annual Review (2005)" presents the latest information on the Indian pharmaceutical research. It highlights the important factors that draw the foreign investors towards the Indian pharmaceutical market to establish themselves. This market research report is indispensable for the manufacturers, investors and all those involved in the pharmaceutical industry and healthcare market to have an in-depth analysis of the business prospects. This report interprets the key issues that influence the success of a pharmaceutical company involved in research and development of drugs.

Content


  • 1. Pharmaceutical and Health Industry
    • 1.1 Industry Overview
      • 1.1.1 Current Size and Business Overview
      • 1.1.2 Development of Outsourcing as New Business Maneuver for Industry Leaders
    • 1.2 Key Development and Challenges with Indian pharmaceutical Industry
    • 1.3 Future Outlook and Recommendations
  • 2. Assessing Indian Pharmaceutical Market
    • 2.1 Pharmaceutical Policy 2002
    • 2.2 Regulatory Environment and Government Initiatives
    • 2.3 Pharmaceutical Registration
    • 2.4 Role of Advertising, Pricing and Distribution Channels in Healthcare Industry Growth
    • 2.5 Summary of Major Findings and Industry Trends
  • 3. Overview of Indian Healthcare and Pharmaceutical Market - 2005
    • 3.1 Global Coverage and World Healthcare Industry Brief
    • 3.2 India: Hub to Pharmaceutical Investors
      • 3.2.1 Industry Overview: Countrywide, Regional and State practices
      • 3.2.2 Indian Socio-Demographic File: Patients, Hospitals and Research Centers
    • 3.3 National Health Policies and Public Programs
    • 3.4 Growth in the Pharmaceutical Industry
      • 3.4.1 Pharmaceutical Manufacturing
        • 3.4.1.1 Types of Drug Manufactures in India
        • 3.4.1.2 Annual India Therapeutic Production (2002-2004)
        • 3.4.1.3 Total estimate of Generic Pharmaceuticals (2002-2004)
      • 3.4.2 Future Investment Growth
      • 3.4.3 Advantages of Conducting Clinical Trials in India
    • 3.5 Challenges
  • 4. Development of Healthcare Systems and Market Potential
    • 4.1 Economic Drivers and Indian Healthcare Industry
    • 4.2 Major Therapeutic Segments, by Sales and Turnover (in millions)
      • 4.2.1 Contract Manufacturing/Freelance Manufacturing
      • 4.2.2 Vertically Integrated Pharmaceutical
      • 4.2.3 Bulk Production of Genetic and Life-saving Drugs
      • 4.2.4 Total Sales of Formulatives and Generic Pharmaceuticals, 2002-2004
      • 4.2.5 Total Production and Consumption of Life-saving and Generic drugs, at domestic level
      • 4.2.6 Total Production and Consumption of Life-saving and Generic drugs, at non-Indian base, by country
    • 4.3 Export and Import Trends in Healthcare and Pharmaceutical Market
      • 4.3.1 Indian Pharmaceutical Exports, by country (in millions) 2003-2004
      • 4.3.2 Annual Imports for Bulk Products and Formulatives, 2003-2004
    • 4.4 Foreign Investments and Impact on Country's GDP Growth (2002-2004)
    • 4.5 Future Outlook and Prospect (2005-2008)
  • 5. A Study on the Value Chain and Supply Chain Model in Indian Pharmaceutical Industry
  • 6. Analysis of Regulatory Frameworks and Policies Initiated in Industry Growth
    • 6.1 Indian Patent Law
    • 6.2 Drug Price Control Order (DPCO)
    • 6.3 National Pharmaceutical pricing Authority (NPPA)
    • 6.4 WTO and its implications
    • 6.5 Insurance and Healthcare in India
  • 7. Role of Recent Information Technology contributing to Market Success
    • 7.1 Bioinformatics
    • 7.2 E-Commerce-Strategies and Impact
    • 7.3 Mergers and Consolidations
  • 8. Research and Development: Gaining New Prospect for Pharmaceutical Marketers
    • 8.1 Develop analogue molecules
    • 8.2 Develop expertise in New Drug Delivery Systems
    • 8.3 Custom Synthesis
    • 8.4 Biotech- New Avenue
    • 8.5 Emerging Technology And Trends In Indian Pharma Industry
  • 9. International Market Responding to Indian Pharmaceutical Industry, country
    • 9.1 US market
    • 9.1 European market
    • 9.1 Rest of the world
    • 9.1 Three Horizons of Growth, 2005-2015
  • 10. Future Outlook For The Indian Pharmaceutical Industry
  • 11. Company Profile of Main Leaders
    • 11.1 Domestic Companies
      • 11.1.1 Apollo Hospitals Company
      • 11.1.2 Cadila Healthcare Ltd.
      • 11.1.3 Cipla Ltd.
      • 11.1.4 Ranbaxy Laboratories Ltd.
      • 11.1.5 Dr Reddy's Laboratories Ltd.
      • 11.1.6 Nicholas Piramal India Ltd.
      • 11.1.7 Sun Pharmaceutical Industries Ltd.
      • 11.1.8 Wockhardt Ltd.
    • 11.2 Multinational Companies
      • 11.2.1 Abbott Laboratories India Ltd.
      • 11.2.2 Burroughs Wellcome India Ltd.
      • 11.2.3 E-Merck (India) Ltd.
      • 11.2.4 Glaxo India Ltd.
      • 11.2.5 Novartis India Ltd.
      • 11.2.6 Hoechst Marion Roussel Ltd.
      • 11.2.7 Pfizer Ltd.
      • 11.2.8 Smithkline Beecham Pharmaceuticals (India) Ltd.
  • List of Tables
    • Table 1. Prescription Statistics
    • Table 2. International Generic Drug Market ($ Billion) & Penetration (%)
    • Table 3. NDSS of the Indian Players
    • Table 4. Indian Biotech companies
    • Table 5. Indian companies - ANDA approvals
    • Table 6. Restricted items for imports under EXIM Policy 2002-2007
  • List of Figures
    • Figure 1. Pharmaceutical Industry Turnover, (Rs Crore)
    • Figure 2. Pharma Market - Segment Wise Break Up (%) 2003-2004
    • Figure 3. Indian Pharmaceuticals exports (%)2003-2004
    • Figure 4. Import (Rs Crore) of bulk drugs and formulations
    • Figure 5. Cost Structure of the Indian Pharmaceutical, (%)
    • Figure 6. ROCE (Pre Tax), (%)2003-2004
    • Figure 7. Prescription share of the top companies, (%)2003-2004
    • Figure 8. Doctor coverage of Pharmaceutical companies, (%)2003-2004
    • Figure 9. Future supply chain
    • Figure 10. Composition of Therapeutic treatments, (%) 2010
    • Figure 11. Research and Development Investment (Rs million)
    • Figure 12. R&D Strategy of Indian Companies
    • Figure 13. Status of New Drug Delivery Systems -Indian Companies
    • Figure 14. Shares of the Companies in the Indian Market, (%)
    • Figure 15. Non-Pharma distribution
    • Figure 16. Ranbaxy's three horizons of growth, 2005-2015
    • Figure 17. Glaxo's three horizons of growth, 2005-2015